These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 11039841)
1. The presence of HLA-DR B1 shared motif does not influence cyclophosphamide and methotrexate cytotoxicity in rheumatoid arthritis patients. Lacki JK; Wassmuth R; Korczowska I; Mackiewicz S; Muller W J Investig Allergol Clin Immunol; 2000; 10(4):235-41. PubMed ID: 11039841 [TBL] [Abstract][Full Text] [Related]
2. Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset. González-Gay MA; Hajeer AH; García-Porrúa C; Dababneh A; Thomson W; Ollier WE; Mattey DL J Rheumatol; 2002 Feb; 29(2):271-5. PubMed ID: 11842822 [TBL] [Abstract][Full Text] [Related]
3. The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. Ahmed SS; Arnett FC; Smith CA; Ahn C; Reveille JD Medicine (Baltimore); 2001 Jul; 80(4):271-8. PubMed ID: 11470988 [No Abstract] [Full Text] [Related]
4. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Miceli-Richard C; Comets E; Verstuyft C; Tamouza R; Loiseau P; Ravaud P; Kupper H; Becquemont L; Charron D; Mariette X Ann Rheum Dis; 2008 Apr; 67(4):478-84. PubMed ID: 17673491 [TBL] [Abstract][Full Text] [Related]
5. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442 [TBL] [Abstract][Full Text] [Related]
6. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. O'Dell JR; Nepom BS; Haire C; Gersuk VH; Gaur L; Moore GF; Drymalski W; Palmer W; Eckhoff PJ; Klassen LW; Wees S; Thiele G; Nepom GT Ann Rheum Dis; 1998 Apr; 57(4):209-13. PubMed ID: 9709176 [TBL] [Abstract][Full Text] [Related]
7. HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. Meyer JM; Evans TI; Small RE; Redford TW; Han J; Singh R; Moxley G J Rheumatol; 1999 May; 26(5):1024-34. PubMed ID: 10332964 [TBL] [Abstract][Full Text] [Related]
8. HLA-DRB1 alleles and shared amino acid sequences in disease susceptibility and severity in patients from eastern France with rheumatoid arthritis. Toussirot E; Auge B; Tiberghien P; Chabod J; Cedoz JP; Wendling D J Rheumatol; 1999 Jul; 26(7):1446-51. PubMed ID: 10405928 [TBL] [Abstract][Full Text] [Related]
9. Role of HLA-DR-DR and DR-DQ associations in the expression of extraarticular manifestations and rheumatoid factor in rheumatoid arthritis. Perdriger A; Chalès G; Semana G; Guggenbuhl P; Meyer O; Quillivic F; Pawlotsky Y J Rheumatol; 1997 Jul; 24(7):1272-6. PubMed ID: 9228123 [TBL] [Abstract][Full Text] [Related]
10. [Presence of HLA-DRB1 alleles in a group of patients with rheumatoid arthritis treated with low doses of sodium aurothiomalate]. Bianucci G; Rombolà G; Tringali M; Curradi C; Bongi SM Clin Ter; 1997 Dec; 148(12):577-92. PubMed ID: 9528193 [TBL] [Abstract][Full Text] [Related]
11. Association of (Q)R/KRAA positive HLA-DRB1 alleles with disease progression in early active and severe rheumatoid arthritis. Seidl C; Koch U; Buhleier T; Möller B; Wigand R; Markert E; Koller-Wagner G; Seifried E; Kaltwasser JP J Rheumatol; 1999 Apr; 26(4):773-6. PubMed ID: 10229395 [TBL] [Abstract][Full Text] [Related]
12. HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis. Laivoranta-Nyman S; Möttönen T; Hermann R; Tuokko J; Luukkainen R; Hakala M; Hannonen P; Korpela M; Yli-Kerttula U; Toivanen A; Ilonen J; Ann Rheum Dis; 2004 Nov; 63(11):1406-12. PubMed ID: 15479890 [TBL] [Abstract][Full Text] [Related]
13. Expression of QK/QR/RRRAA or DERAA motifs at the third hypervariable region of HLA-DRB1 and disease severity in rheumatoid arthritis. Khani-Hanjani A; Lacaille D; Horne C; Chalmers A; Hoar DI; Balshaw R; Keown PA J Rheumatol; 2002 Jul; 29(7):1358-65. PubMed ID: 12136889 [TBL] [Abstract][Full Text] [Related]
14. Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF). Barrera P; Balsa A; Alves H; Westhovens R; Maenaut K; Cornélis F; Fritz P; Bardin T; Ceu Maia M; Lopes-Vaz A; Pascual Salcedo D; de la Concha E; Radstake T; van de Putte LB; Migliorini P; Prudhomme JF; Charron D; Spyropoulou M; Mendes A; Spaepen M; Martinez M; Stavropoulos C; J Rheumatol; 2001 May; 28(5):968-74. PubMed ID: 11361224 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414 [TBL] [Abstract][Full Text] [Related]
16. Noninherited maternal antigens do not play a role in rheumatoid arthritis susceptibility in Europe. European Consortium on Rheumatoid Arthritis Families. Barrera P; Balsa A; Alves H; Westhovens R; Maenaut K; Cornélis F; Fritz P; Bardin T; de Almeida G; Lopes-Vaz A; Pascual Salcedo D; de la Concha EG; Radstake TR; van de Putte LB; Migliorini P; Prud'homme JF; Charron D; Spyropoulou M; Mendes A; Spaepen M; Martinez M; Lepage V; Stravopoulos C Arthritis Rheum; 2000 Apr; 43(4):758-64. PubMed ID: 10765920 [TBL] [Abstract][Full Text] [Related]
17. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Berkun Y; Levartovsky D; Rubinow A; Orbach H; Aamar S; Grenader T; Abou Atta I; Mevorach D; Friedman G; Ben-Yehuda A Ann Rheum Dis; 2004 Oct; 63(10):1227-31. PubMed ID: 15361376 [TBL] [Abstract][Full Text] [Related]
18. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699 [TBL] [Abstract][Full Text] [Related]
19. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721 [TBL] [Abstract][Full Text] [Related]
20. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Martinez A; Salido M; Bonilla G; Pascual-Salcedo D; Fernandez-Arquero M; de Miguel S; Balsa A; de la Concha EG; Fernandez-Gutierrez B Arthritis Rheum; 2004 Apr; 50(4):1077-82. PubMed ID: 15077289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]